Recruiting

Psychosis Treatment

Sponsor:

Northwell Health

Code:

NCT06969755

Conditions

Schizophenia Disorder

Eligibility Criteria

Sex: All

Age: 18 - 35

Healthy Volunteers: Not accepted

Interventions

aripiprazole

risperidone

clozapine

Study Details

Brief summary:

This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.

Conditions

Schizophenia Disorder

Study ID

NCT06969755

Start date

Sep 4, 2024

Status verified date

Jul, 2026

Completion date

Jul 30, 2030

Anticipated

Primary completion date

Jul 30, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 35

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Aged 18 to 35.
2. DSM5 diagnosis (as determined by the SCID5) of schizophrenia, schizoaffective disorder, schizophreniform disorder.
3. Current positive symptoms rated ≥4 (moderate) on one or more of the following BPRS positive subscale items: unusual thought content, conceptual disorganization, hallucinatory behavior, suspiciousness.
4. Preserved striatal connectivity, as determined by screening MRI scan
5. Absence of the MC4R high-risk genotype, as determined by genetic testing
6. Absence of the HLA-DQB1 high-risk genotype, as determined by genetic testing
7. In an early phase of illness as defined by having taken antipsychotic drugs for a cumulative lifetime period of 4 weeks or less (with exceptions of very low doses for other off-label indications, e.g. sleep)
8. Ability to provide informed consent

Exclusion Criteria:

1. The patient reports or medical records state a serious neurological or endocrine disorder at screening that the investigator determines could interfere with the interpretation of the efficacy or safety measurements
2. An abnormal EKG at screening that the investigator determines could interfere with the interpretation of the efficacy or safety measurements
3. Any medical condition which requires treatment with a medication with psychotropic effects.
4. Significant risk of suicidal or homicidal behavior (i.e. 'severe' risk on the Columbia Suicide Scale, a 'hostility' score of 7 on the BPRS, or an answer of 'yes' on questions 4,5 or 6 on the CDSS).
5. Cognitive limitations, or any other factor that would preclude potential participants providing informed consent
6. Contraindications to MRI (e.g. pacemaker).
7. Meeting SCID-5 substance use disorder moderate or severe for any substance, other than nicotine within 3 months of screening visit. Meeting SCID5 substance use disorder mild for any substance other than cannabis, alcohol, or nicotine for less than 3 months prior to screening visit, or a positive urine baseline drug screen with a substance other than nicotine, alcohol, or cannabis
8. Suspected DSM5 intellectual disability based upon clinical interview and psychosocial history, as well as screening with the Weschler Test for Adult Reading (IQ score <71)
9. Prior psychosurgery
10. Pregnancy (self-report)
11. Seizure disorder (self-report)

\-

Study Design

Enrollment

180 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: risperidone

risperidone treatment provided per protocol

active comparator: aripiprazole

aripiprazole treatment per protocol

active comparator: clozapine

clozapine treatment per protocol

Interventions

aripiprazole

aripiprazole arm (titrated dose)

risperidone

risperidone arm (titrated dose)

clozapine

clozapine (titrated dose)

Primary outcome measure

  • Total change in BPRS Symptoms [ Time Frame: 12 weeks ]

Central Contacts and Locations

Central contacts

Locations

The University of Alabama at Birmingham

Recruiting

Birmingham, Alabama, United States, 35294

Contacts

University of California San Diego

Recruiting

La Jolla, California, United States, 92093

Contacts

McLean

Recruiting

Belmont, Massachusetts, United States, 02478

Contacts

Feinstein Institute for Medical Research

Recruiting

Glen Oaks, New York, United States, 11004

Contacts

Taylor Marzouk Coordinator

718-470-8905tmarzouk@northwell.edu

Centre for Addiction and Mental Health

Recruiting

Toronto, Canada

Contacts

More Information

Sponsor

Northwell Health

Last update posted

Jul 31, 2026

Last verified

Jul, 2026

Keywords

  • Schizophrenia

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Northwell Health on 2026-07-31.